VanEck Biotech ETF (NASDAQ:BBH) Sees Large Growth in Short Interest

VanEck Biotech ETF (NASDAQ:BBH) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,900 shares, an increase of 107.1% from the January 15th total of 1,400 shares. Based on an average daily volume of 11,600 shares, the days-to-cover ratio is currently 0.3 days.

Hedge Funds Weigh In On VanEck Biotech ETF

Several hedge funds and other institutional investors have recently bought and sold shares of BBH. Farther Finance Advisors LLC bought a new stake in shares of VanEck Biotech ETF during the 4th quarter valued at about $32,000. Truvestments Capital LLC acquired a new position in VanEck Biotech ETF during the 3rd quarter worth approximately $44,000. FSA Wealth Management LLC bought a new stake in shares of VanEck Biotech ETF in the 3rd quarter worth approximately $54,000. Coastline Trust Co bought a new stake in shares of VanEck Biotech ETF in the third quarter valued at approximately $59,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of VanEck Biotech ETF during the 4th quarter valued at approximately $81,000. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Stock Up 0.2 %

NASDAQ:BBH traded up $0.30 during trading hours on Thursday, hitting $160.84. 1,988 shares of the company were exchanged, compared to its average volume of 10,472. VanEck Biotech ETF has a one year low of $151.35 and a one year high of $183.64. The company has a fifty day simple moving average of $161.59 and a 200 day simple moving average of $170.14.

VanEck Biotech ETF Announces Dividend

The company also recently declared a dividend, which was paid on Tuesday, December 24th. Shareholders of record on Monday, December 23rd were issued a dividend of $1.2517 per share. The ex-dividend date was Monday, December 23rd.

About VanEck Biotech ETF

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.